跳转至内容
Merck

SML1967

Sigma-Aldrich

N6-(4-Hydroxybenzyl) adenine riboside

≥98% (HPLC)

别名:

N-[(4-Hydroxyphenyl)methyl]adenosine, N6-(4-Hydroxybenzyl)-adenosine, NHBA, T1-11

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H19N5O5
分子量:
373.36
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

OC[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3NCC4=CC=C(O)C=C4)[C@H](O)[C@@H]1O

InChI

1S/C17H19N5O5/c23-6-11-13(25)14(26)17(27-11)22-8-21-12-15(19-7-20-16(12)22)18-5-9-1-3-10(24)4-2-9/h1-4,7-8,11,13-14,17,23-26H,5-6H2,(H,18,19,20)/t11-,13-,14-,17-/m1/s1

InChI 密鑰

UGVIXKXYLBAZND-LSCFUAHRSA-N

生化/生理作用

N6-(4-Hydroxybenzyl) adenine riboside (NHBA) is an orally available and brain penetrant active active ingredient of Gastrodia elata rhizomes used for the treatment of insomnia. N6-(4-Hydroxybenzyl) adenine riboside is an adenosine A2A receptor and the equilibrative nucleoside transporter 1 (ENT1) agonist. It exhibits sedative and hypnotic effects by binding to adenosine A1 and A2A receptors in mice. N6-(4-Hydroxybenzyl) adenine riboside exerted a therapeutic effect on HD transgenic mouse by decreasing protein level of polyglutamine-expanded huntingtin in the striatum.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Nai-Kuei Huang et al.
PloS one, 6(6), e20934-e20934 (2011-06-30)
Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments
Jhih-Bin Chen et al.
ChemMedChem, 6(8), 1390-1400 (2011-06-22)
A novel compound, N⁶-(4-hydroxybenzyl)adenosine, isolated from Gastrodia elata and which has been shown to be a potential therapeutic agent for preventing and treating neurodegenerative disease, was found to target both the adenosine A(2A) receptor (A(2A) R) and the equilibrative nucleoside
An-Hsun Chou et al.
Neuropharmacology, 99, 308-317 (2015-08-10)
More studies are required to develop therapeutic agents for treating spinocerebellar ataxia type 3 (SCA3), which is caused by mutant polyglutamine-expanded ataxin-3 and is the most prevalent subtype of spinocerebellar ataxias. T1-11 [N6-(4-Hydroxybenzyl) adenosine], isolated from a Chinese medicinal herb

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门